Cancer Immunotherapy - Global Strategic Business Report

The global market for Cancer Immunotherapy was valued at US$174.9 Billion in 2024 and is projected to reach US$378.5 Billion by 2030, growing at a CAGR of 13.7% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Cancer Immunotherapy market.

Global Cancer Immunotherapy Market - Key Trends & Drivers Summarized

Why Is Cancer Immunotherapy Gaining Momentum in Oncology?

Cancer immunotherapy has emerged as one of the most promising and transformative treatment modalities in oncology, revolutionizing how cancer is treated. Unlike traditional therapies such as chemotherapy and radiation, which target cancer cells directly, immunotherapy harnesses the body’s immune system to recognize and attack cancer cells. This approach has shown remarkable efficacy in treating several types of cancer, including melanoma, lung cancer, and certain types of blood cancers. The ability of immunotherapy to provide durable responses, sometimes leading to complete remission, even in late-stage cancers, has made it a game-changing treatment option. Immunotherapy drugs, such as checkpoint inhibitors, CAR-T cell therapy, and monoclonal antibodies, are being increasingly integrated into standard cancer treatment protocols, providing new hope to patients who may not respond well to conventional therapies.

The success of immunotherapy is also attributed to its potential for long-term cancer control. For some patients, immunotherapy has shown the ability to provide lasting protection by creating an immune memory that can continue to recognize and destroy cancer cells even after treatment has ended. This durability sets it apart from many traditional treatments that often need continuous administration. With increasing clinical success and a growing number of immunotherapy drugs receiving regulatory approvals, this approach is rapidly becoming a cornerstone of cancer treatment across the globe.

How Are Technological Advancements and New Discoveries Shaping the Immunotherapy Landscape?

Technological advancements and groundbreaking discoveries are significantly expanding the capabilities of cancer immunotherapy. One of the most significant developments has been the rise of checkpoint inhibitors, such as PD-1 and CTLA-4 inhibitors, which work by blocking proteins that prevent the immune system from attacking cancer cells. These drugs have become a standard treatment for cancers like melanoma and non-small cell lung cancer, among others, and are now being tested in combination with other therapies to enhance their effectiveness. The development of personalized immunotherapies, particularly CAR-T cell therapy, which involves engineering a patient’s own T-cells to target and kill cancer cells, has also generated a great deal of excitement. CAR-T therapy has demonstrated extraordinary success in treating certain blood cancers, particularly in patients who have exhausted other treatment options.

Emerging technologies like artificial intelligence (AI) and machine learning are playing an increasingly important role in accelerating immunotherapy research. AI is being used to analyze vast datasets to identify new biomarkers and predict patient responses to immunotherapy, improving personalized treatment strategies. Advancements in gene editing tools like CRISPR are also being explored to enhance the effectiveness of T-cell therapies and develop next-generation immunotherapies. Additionally, research into cancer vaccines and oncolytic viruses - viruses that can infect and kill cancer cells - shows promising potential to further expand the immunotherapy toolkit. These innovations are expected to push the boundaries of what immunotherapy can achieve, potentially unlocking new treatments for cancers that have been historically difficult to treat.

How Are Changing Consumer Preferences and Healthcare Trends Impacting Immunotherapy Demand?

The rising demand for more effective, less toxic cancer treatments is driving the adoption of immunotherapy across various healthcare settings. Patients today are more informed about their treatment options and increasingly seek therapies that offer fewer side effects compared to traditional treatments like chemotherapy, which is known for its harsh adverse effects such as fatigue, nausea, and immune suppression. Immunotherapy is often better tolerated, with many patients experiencing fewer or less severe side effects, making it an attractive option for those seeking a higher quality of life during treatment. This shift in patient preferences toward targeted, less invasive therapies is accelerating the adoption of immunotherapies.

Moreover, immunotherapy is becoming more accessible, thanks to the growing number of approved drugs and expanded indications for existing treatments. Immunotherapies that were initially approved for a narrow range of cancers are now being explored and authorized for use in other cancer types, creating broader treatment opportunities. The rising demand for personalized medicine is another significant factor influencing the market, as patients and healthcare providers increasingly seek tailored treatments that are specific to an individual’s genetic makeup or tumor profile. As immunotherapy often requires biomarker testing to identify eligible patients, it aligns well with the trend toward personalized cancer care, further driving its uptake in oncology practices worldwide.

Growth in the Cancer Immunotherapy Market Is Driven by Several Factors

The growth in the cancer immunotherapy market is driven by several factors, including advancements in drug development, increasing prevalence of cancer, and the rising demand for personalized and targeted treatments. Technological breakthroughs, particularly in the development of checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines, have opened new avenues for treating both solid tumors and hematologic cancers. The success of these therapies in achieving durable responses and even long-term remission in some patients has fueled further research and investment in the field. Additionally, the ongoing expansion of approved immunotherapies to treat a wider range of cancers is contributing to market growth, as more patients become eligible for these innovative treatments.

Another key driver is the increasing focus on combination therapies, where immunotherapy is used alongside chemotherapy, radiation, or other targeted therapies to enhance treatment efficacy. This approach is showing promising results in clinical trials, as combining therapies can help overcome resistance and improve patient outcomes. The rise in biomarker-based diagnostics is also playing a significant role, as it enables oncologists to identify which patients are most likely to benefit from immunotherapy, thus optimizing treatment selection and improving success rates. Furthermore, the growing investment in research and development, both by pharmaceutical companies and academic institutions, is accelerating the discovery of new immunotherapies and expanding the market’s potential. As these trends continue to evolve, the cancer immunotherapy market is poised for robust growth, offering new hope for cancer patients worldwide.

Report Scope

The report analyzes the Cancer Immunotherapy market, presented in terms of units. The analysis covers the key segments and geographic regions outlined below.

Segments: Product (Monoclonal Antibodies, Cytokines & Immunomodulators, Other Products); Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, Other Cancer Types).

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Monoclonal Antibodies segment, which is expected to reach US$266.2 Billion by 2030 with a CAGR of a 14.5%. The Cytokines & Immunomodulators segment is also set to grow at 12.8% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $44.5 Billion in 2024, and China, forecasted to grow at an impressive 17.9% CAGR to reach $94.0 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Cancer Immunotherapy Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Cancer Immunotherapy Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Cancer Immunotherapy Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Advaxis Inc., Amgen Inc., Astrazeneca, Bayer AG, Bristol-Myers Squibb and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 42 companies featured in this Cancer Immunotherapy market report include:

• Advaxis Inc.
• Amgen Inc.
• Astrazeneca
• Bayer AG
• Bristol-Myers Squibb
• Celgene Corporation
• ELI Lilly and Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline Plc
• Immunomedics Inc.
• Janssen Global Services, LLC (Johnson and Johnson)
• Merck
• Novartis
• Pfizer
• Seattle Genetics, Inc.
• Spectrum Pharmaceuticals, Inc.

Tariff Impact Analysis: Key Insights for 2025

Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.

The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

What’s Included in This Edition:

• Tariff-adjusted market forecasts by region and segment
• Analysis of cost and supply chain implications by sourcing and trade exposure
• Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

• Finalized tariff impacts and new trade agreement effects
• Updated projections reflecting global sourcing and cost shifts
• Expanded country-specific coverage across the industry